

8 October 2024

ASX Market Announcements Office  
ASX Compliance Pty Ltd  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

Dear Sir/Madam,

**NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)**

Botanix Pharmaceuticals Limited (ASX: BOT, **Botanix or the Company**) advises that on 7 October 2024 it issued 3,422,643 new fully paid ordinary shares (**New Shares**) on exercise of 3,422,643 \$0.089, 7 October 2024 unquoted options.

The Company hereby provides notification under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) of the issue of the New Shares. The Corporations Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Corporations Act. By the Company giving this notice (**Notice**), a sale of the New Shares will fall within the exemption in section 708A(5) of the Corporations Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Corporations Act, the Company gives notice that:

- (a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this Notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this Notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this Notice, there is no excluded information, within the meanings of section 708A(7) and 708A(8) of the Corporations Act.

By order of the Board



**Susan Park**  
Company Secretary

Release authorised by the Board of Directors.

## About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra*™ for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

## For more information, please contact:

### General enquiries

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6555 2945  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

### Investor enquiries

Hannah Howlett  
WE Communications  
P: +61 450 648 064  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

### Media enquiries

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)